{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T20:29:41Z","timestamp":1768681781097,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clinthera.2021.01.005","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T20:19:32Z","timestamp":1611865172000},"page":"526-534.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics and Safety of Extended-release Ranolazine in Korean and White Healthy Subjects"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2785-4383","authenticated-orcid":false,"given":"Hyounggyoon","family":"Yoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5281-8811","authenticated-orcid":false,"given":"Deok Yong","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seo Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-Youn","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1713-9194","authenticated-orcid":false,"given":"SeungHwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.01.005_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00129784-200303001-00001","article-title":"Stable Angina","volume":"3","author":"Steg","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2021.01.005_bib2","first-page":"407","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"41","author":"Knuuti","year":"2020"},{"key":"10.1016\/j.clinthera.2021.01.005_bib3","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1056\/NEJMcp042317","article-title":"Chronic stable angina","volume":"352","author":"Abrams","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clinthera.2021.01.005_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/01.crd.0000161979.62749.e7","article-title":"Ranolazine\u2217: a metabolic modulator for the treatment of chronic stable Angina","volume":"13","author":"Anderson","year":"2005","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.clinthera.2021.01.005_bib5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0002-9149(99)00190-3","article-title":"A\u00a0controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents","volume":"84","author":"Pepine","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2021.01.005_bib6","author":"Agency"},{"key":"10.1016\/j.clinthera.2021.01.005_bib7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2165\/00003495-200666050-00010","volume":"66","author":"Siddiqui","year":"2006","journal-title":"Ranolazine Drugs"},{"key":"10.1016\/j.clinthera.2021.01.005_bib8","article-title":"Ranolazine: a contemporary review","volume":"5","author":"Rayner-Hartley","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2021.01.005_bib9","series-title":"Population Pharmacokinetics of Ranolazine","year":"2005"},{"key":"10.1016\/j.clinthera.2021.01.005_bib10","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","article-title":"Ethnic factors in the acceptability of foreign clinical data E5 (R1)","year":"1998"},{"key":"10.1016\/j.clinthera.2021.01.005_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1067\/mcp.2001.117703","article-title":"Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin","volume":"70","author":"Yu","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2021.01.005_bib12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/01.ftd.0000164293.75854.11","article-title":"MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations","volume":"27","author":"Lee","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2021.01.005_bib13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/2047487312450133","article-title":"Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine in Stable Angina (CARISA) randomized trial","volume":"19","author":"Send\u00f3n","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.clinthera.2021.01.005_bib14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"Jama"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:59Z","timestamp":1758963299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821000096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0149291821000096"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and Safety of Extended-release Ranolazine in Korean and White Healthy Subjects","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}